Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRUSMI-Ambulance sonothrombolysis in STEMI
2019-001883-31Phase 2Completed
- Sponsor
- VU Univesity Medical Center (VUmc)
- Start
- Feb 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perflutren lipid microspheres in acute ST-segment elevation myocardial infarction (STEMI), sponsored by VU Univesity Medical Center (VUmc). Primary endpoints: Safety: ventricular arrhythmias and shock before PCI and Feasibility of ambulance sonothrombolysis. Started Feb 2020; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2019-001883-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001883-31.